Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Investigate the Activity of Neoadjuvant PRTX007 Combined With Pembrolizumab in Participants With Stage III Melanoma (INFLECTION-003)

NCT07565285 is registered in ClinicalTrials.gov with Primmune Therapeutics, Inc. as lead sponsor.

NCT NCT07565285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07565285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Investigate the Activity of Neoadjuvant PRTX007 Combined With Pembrolizumab in Participants With Stage III Melanoma (INFLECTION-003)
Lead sponsor
Primmune Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 1, 2026
Completion date
June 30, 2029
Enrollment
48 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iii